Search Within

William D Travis

Formats
  1. Journal Article (357)
  2. Meeting Abstract (286)
  3. Book Section (60)
  4. Review (20)
  5. Guidelines (9)
  6. Editorial (8)
  7. Correspondence (6)
  8. Book Whole (3)
Groups
  1. Department of Pathology and Laboratory Medicine (749)
  2. Surgery (280)
  3. Department of Medicine (209)
  4. Solid Tumor Oncology Division (194)
  5. Thoracic Oncology (185)
  6. GSK Faculty (160)

More Groups

People
  1. Natasha Rekhtman (193)
  2. Prasad Adusumilli (156)
  3. Valerie Rusch (144)
  4. Marc Ladanyi (94)
  5. Jennifer Sauter (74)
  6. Kyuichi Kadota (73)

More People

Years
  1. 2025 (17)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (34)
  5. 2021 (38)
  6. 2020 (38)

More Years

Publications
  1. Journal of Thoracic Oncology (182)
  2. Modern Pathology (109)
  3. Laboratory Investigation (95)
  4. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed (44)
  5. Journal of Clinical Oncology (22)
  6. American Journal of Surgical Pathology (21)

More Publications

Publishers
  1. Elsevier Inc. (207)
  2. Nature Research (109)
  3. Nature Publishing Group (105)
  4. International Agency for Research on Cancer (44)
  5. Lippincott Williams & Wilkins (26)
  6. American Association for Cancer Research (23)

More Publishers

Results (749)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathological classification of thymic tumours in the molecular age: Proposals for the next WHO classification
    Meeting Abstract

    Travis, W.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Neuroendocrine tumours
    Meeting Abstract

    Travis, W.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis Program at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Pietanza, M. C.; Varghese, A.; Won, H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Spread through alveolar spaces (STAS): A newly recognized pattern of invasion in lung adenocarcinoma associated with increased recurrence in patients undergoing limited resection for <= 2cm tumors
    Meeting Abstract

    Nitadori, J.; Kadota, K.; Sima, C. S.; Ujiie, H.; Rizk, N. P.; Rusch, V. W.; Travis, W. D.; Adusumilli, P. S.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer: Implications for immunotherapy
    Meeting Abstract

    Lee, M. C.; Kadota, K.; Ujiie, H.; Rizk, N. P.; Travis, W. D.; Rusch, V. W.; Sadelain, M.; Adusumilli, P. S.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • In patients with stage I lung adenocarcinoma, tumor budding is a significant prognostic factor for recurrence, independent of the IASLC/ATS/ERS classification, and correlates with a protumor immune microenvironment
    Meeting Abstract

    Kadota, K.; Yeh, Y. C.; Rizk, N. P.; Rusch, V. W.; Adusumilli, P. S.; Travis, W. D.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Reclassification of resected non-small cell lung carcinomas originally diagnosed as squamous cell carcinoma, after reevaluation using immunohistochemical analysis (P40, P63, TTF-1, and napsin A): Memorial Sloan-Kettering Cancer Center experience
    Meeting Abstract

    Kadota, K.; Nitadori, J.; Rusch, V. W.; Rekhtman, N.; Sarkaria, I. S.; Adusumilli, P. S.; Travis, W. D.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Tumor budding and nuclear grade, but not histologic subtype, are significant prognostic factors, independent of TNM stage, in patients with lung squamous cell carcinoma
    Meeting Abstract

    Kadota, K.; Nitadori, J.; Finley, D. J.; Rusch, V. W.; Adusumilli, P. S.; Travis, W. D.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Major pathologic response (<= 10% viable tumor) following neoadjuvant chemotherapy as a surrogate for overall survival in patients with pathologically documented stage IIIA (N2) lung adenocarcinomas
    Meeting Abstract

    Chaft, J. E.; Hellmann, M. D.; Rusch, V. W.; Travis, W. D.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of 18f-FDG PET guided optimization of neoadjuvant chemotherapy for resectable non-small cell lung cancer
    Meeting Abstract

    Chaft, J. E.; Hellmann, M. D.; Dunphy, M.; Jappe, W.; Sima, C. S.; Downey, R. J.; Travis, W. D.; Azzoli, C. G.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save